EQS-News: BRAIN Biotech announces buy-out of minorities, new continental European production site, and expansion of its Baking Application Center

BRAIN Biotech announces buy-out of minorities, new continental European production site, and expansion of its Baking Application Center

• Breatec B.V. is now fully owned by BRAIN Biotech AG following a minority buyout
• New and enlarged production site will open close to Eindhoven, NL
• Expanded competence center for enzyme-based baking applications

ZWINGENBERG, Germany, May 20, 2025 – BRAIN Biotech, a leading provider of integrated solutions for the biologization of industry, is pleased to announce that it has bought out the remaining minority shares in its Dutch subsidiary Breatec B.V.. With the closure of this transaction, all businesses in the BRAINBiocatalysts division are now fully owned by BRAIN Biotech AG. 

Coinciding with this share purchase was the signing of a lease contract for a new site in the Netherlands. The search for a new site had been ongoing due to the commercial successes and rapidly increasing sales volumes, particularly in the flour and bakery enzymes business. The new site will have a significantly larger footprint and is again situated in the south of the Netherlands next to the major city of Den Bosch, conveniently located alongside the main A59 highway. The new site will operate as an integrated continental European production and warehousing hub. In addition, the company will also reestablish a test laboratory for baked goods there. An expanded competence center for enzyme-based baking applications will promote customer intimacy and thus the joint development of new customer products. 

Because of this investment, the site in Büttelborn, Germany, which specializes in enzymes and starter cultures for the beverage production, will be shut down, and its production operations will be moved step by step to the new site in the Netherlands. The company’s competence center for enzymes in the beverage industry and its people formerly located in Büttelborn, Germany, will move to the BRAIN Biotech R&D campus in Zwingenberg, Germany, further accelerating innovation and facilitating increased application focus.

Expansion of customer service and exploitation of further synergies

As a result of the above transactions, the company expects to reap significant synergies, particularly in sharing application knowledge and aligning its operational footprint. In addition, the concentration of warehousing and production on one continental European location will also generate financial synergies. A limited reduction of staff is foreseen mainly affecting the Büttelborn site.

Pieter-Jan Heijkoop, Vice President Food enzymes in the BRAINBiocatalysts segment says: “I am extremely pleased and proud of this milestone investment. It demonstrated our firm commitment to meeting customer needs through superior application skills while optimizing our production facilities. The new location is truly a marvelous place. The Baking Application Center we intend to implement, which will also offer the opportunity to experience product prototypes with all the senses, should excite our customers. The site should be fully operational before the end of 2025.”

BRAIN Biotech CFO Michael Schneiders adds: “Buying out the Breatec minority shares was always our intention, and we now had an optimal window to successfully execute this transaction. Given the strong growth track record of our bakery enzymes business, we needed to establish a new facility, and the realization of synergies was clearly also a key driver in establishing this new site.”

Despite the ongoing relocation of the production facility, deliveries to customers will continue as usual and be without interruption.

+++

BRAIN Biotech Group

The BRAIN Biotech Group is a leading company in the research, development and production of specialty enzymes with a focus on the food and life science industries. In addition, the Group develops microbial production organisms and scalable bioprocesses for the economic production of specialty enzymes and other proteins. Customized innovative biological solutions for more sustainable products and processes round off the portfolio.

The parent company of the BRAIN Biotech Group is BRAIN Biotech AG. The business activities of the integrated company are divided into the two segments BRAINBiocatalysts (development, production and distribution of specialty enzymes, microorganisms, ingredients) and BRAINBioIncubator (research-intensive development projects, pharmaceuticals). For production, the Group operates fermentation plants in the UK as well as production facilities in continental Europe and the USA.

BRAIN Biotech has been listed on the Frankfurt Stock Exchange since February 9, 2016 (Ticker: BNN; ISIN DE0005203947 / WKN 520394). The company employs around 300 people at several locations and generated revenues of EUR 54.6 million in the 2023/24 financial year. Further information can be found at: www.brain-biotech-group.com.

Contact Media
Dr. Stephanie Konle
PR & Corporate Communications
Phone: +49 6251 9331-70
Email: stk@brain-biotech.com

Contact Investor Relations
Martina Schuster
Investor Relations
Phone: +49 6251 9331-69
Email: ms@brain-biotech.com

The BRAIN Biotech Group on social media and on the internet:

BRAIN Biotech Gruppe

Web: www.brain-biotech-group.com

LinkedIn: https://www.linkedin.com/company/brainbiotech

Threads: https://www.threads.net/@brainbiotechag

Bluesky: https://bsky.app/profile/brain-biotech-group.com

X: https://x.com/BRAINbiotech

Youtube: https://www.youtube.com/channel/UCS33HJqku674X22UQ8QIsyg

Biocatalysts Ltd (Production, Distribution)

Website: https://www.biocatalysts.com/

LinkedIn: Biocatalysts Ltd on LinkedIn / BRAIN-Biocatalysts Life Science Solutions on LinkedIn

BRAIN Biotech Zwingenberg (Technologies & R&D Services)

Website: www.brain-biotech.com

LinkedIn: BRAIN Biotech Technologies & Services

AnalyticonDiscovery (R&D)

Web: https://ac-discovery.com/

LinkedIn: https://www.linkedin.com/company/analyticon-discovery/

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management.

Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance of and future developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors.

BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.